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Abstract
 
The bradykinin B
 
1
 
-receptor is strongly upregulated under
chronic inflammatory conditions. However, the mechanism
and reason are not known. Because a better understanding
of the mechanism of the upregulation will help in under-
standing its potential importance in inflammation, we have
studied the molecular mechanism of B
 
1
 
-receptor upregula-
tion in cultured human lung fibroblasts (IMR 90) in re-
sponse to IL-1
 
b 
 
and the B
 
1
 
-agonist [des-Arg
 
10
 
]-kallidin. We
show that treatment of human IMR 90 cells by IL-1
 
b
 
 stimu-
lates the expression of both B
 
1
 
-receptor mRNA and protein.
The latter was studied by Western blot analysis using anti-
peptide antibodies directed against the COOH-terminal part
of the human B
 
1
 
-receptor. We furthermore report the novel
observation that the B
 
1
 
-receptor is upregulated by its own
agonist which was completely blocked by the specific B
 
1
 
-
antagonist [des-Arg
 
10
 
-Leu
 
9
 
]-kallidin, indicating an upregu-
lation entirely mediated through cell surface B
 
1
 
-receptors.
The increased population of B
 
1
 
-receptors was functionally
coupled as exemplified by an enhancement of the B
 
1
 
-agonist
induced increase in free cytosolic calcium. Upregulation by
the B
 
1
 
-agonist was blocked by a specific protein kinase C in-
hibitor. B
 
1
 
-agonist–induced upregulation was correlated to
the induction of transcription factor nuclear factor 
 
k
 
B
(NF-
 
k
 
B) which efficiently bound to the NF-
 
k
 
B–like sequence
located in the promoter region of the human B
 
1
 
-receptor
gene. This correlation was further confirmed by reporter
gene assays which showed that this NF-
 
k
 
B–like sequence, in
the B
 
1
 
-receptor promoter context, could contribute to IL-1
 
b
 
and DLBK-induced B
 
1
 
-receptor transcription activation,
and by the effect of NF-
 
k
 
B inhibitor pyrrolidinedithiocar-
bamate which diminished both B
 
1
 
-receptor upregulation and
NF-
 
k
 
B activation. NF-
 
k
 
B is now recognized as a key in-
flammatory mediator which is activated by the B
 
1
 
-agonist
but which is also involved in B
 
1
 
-receptor upregulation. (
 
J.
Clin. Invest.
 
 1998. 101:2080–2091.) Keys words: bradykinin 
 
•
 
B
 
1
 
-receptor 
 
•
 
 NF-
 
k
 
B 
 
• 
 
gene expression 
 
•
 
 inflammation
 
Introduction
 
It is now well known that the responses to vasoactive kinin
peptides are mediated through the activation of two receptors
termed B
 
1
 
 and B
 
2
 
, which have been first defined on the basis of
the structure–function relationships of their agonists and an-
tagonists (1). The natural agonists of the B
 
2
 
-receptor are the
nonapeptide bradykinin (BK)
 
1
 
 and the decapeptide Lys-BK
(kallidin) which are generated by the proteolytic action of the
serine protease kallikrein from the protein precursor kinino-
gen (2). BK and Lys-BK are weak B
 
1
 
-receptor agonists, but
the cleavage of these two B
 
2
 
-agonists by arginine carboxypep-
tidases produces the high affinity B
 
1
 
-receptor agonists, [des-
Arg
 
9
 
]-BK and [des-Arg
 
10
 
]-kallidin (DLBK), respectively (1).
Cloning studies confirmed the existence of B
 
1
 
- and B
 
2
 
-recep-
tors (3–8), which showed that they belong to the superfamily
of seven transmembrane domain G protein–coupled receptors.
Up- and downregulation has been reported for the B
 
2
 
-receptor
(9–11). The B
 
1
 
-receptor, which is only weakly expressed under
physiological conditions, is strongly induced in injured tissue,
which can be mimicked in vitro by inflammatory mediators
such as bacterial lypopolysaccharides and IL-1
 
b 
 
(12).
BK is involved in physiological and pathological processes
including vasodilatation, diuresis and natriuresis, cell contrac-
tion or relaxation, increased vascular permeability, pain, and
inflammation (2, 13–15). Several observations support also an
involvement of BK in allergic airway inflammation (16–20).
Furthermore, in cultured human lung fibroblasts, BK activates
nuclear factor 
 
k
 
B (NF-
 
k
 
B) and a concomitant gene expression
of the proinflammatory cytokine IL-1
 
b 
 
(21). NF-
 
k
 
B appears to
be a key mediator in allergic inflammation as it activates a
large number of inducible genes that encode inflammatory
proteins (cytokines, enzymes, receptors, etc.; reference 22).
On the contrary, inhalation of nebulized B1-agonist [des-
Arg
 
9
 
]-BK in asthmatic volunteers is without effect, suggesting
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Abbreviations used in this paper:
 
 ACE, angiotensin converting en-
zyme; BK, bradykinin; [Ca
 
2
 
1
 
]
 
i
 
, intracellular calcium concentration;
CHX, cholera toxin; DLBK, [des-Arg
 
10
 
]-kallidin; EMSA, electro-
phoretic mobility shift assay; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; HB
 
1
 
, human B
 
1
 
; NF-
 
k
 
B, nuclear factor 
 
k
 
B; PKC,
protein kinase C; PTX, pertussis toxin; PDTC, pyrrolidinedithiocar-
bamate.
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no role of this carboxypeptidase metabolite of BK in allergic
airway inflammation (19, 20). However, several observations
suggest that the B
 
1
 
-receptor may play a role under such chronic
inflammatory conditions: (
 
a
 
) the B
 
1
 
-receptor is strongly in-
duced (sevenfold) in cultured human lung fibroblasts upon
treatment with the proinflammatory cytokine IL-1
 
b 
 
(3) and
in several other tissues after injury or inflammation (12); (
 
b
 
) it
was suggested recently that B
 
1
 
-receptors can amplify and take
the relay of B
 
2
 
-receptors in chronic pathologies (12) which is
now supported by the observation that the B
 
1
 
-receptor, unlike
the B
 
2
 
-receptor, does not desensitize (23); and (
 
c
 
) the accumu-
lation of B
 
1
 
-agonist during sepsis, where the disappearance of
angiotensin converting enzyme (ACE) from the pulmonary
circulation favors the formation of B
 
1
 
-agonist DLBK by argi-
nine carboxypeptidases from Lys-BK (24). Furthermore, the
absence of an effect of [des-Arg
 
9
 
]-BK in the earlier studies of
Polosa and colleagues (19, 20) is now attributed to the fact that
[des-Arg
 
9
 
]-BK is not the natural human B
 
1
 
-receptor agonist
since recent studies have clearly demonstrated that the B
 
1
 
-ago-
nist [des-Arg
 
9
 
]-BK has a 1000-fold lower affinity for the human
B
 
1
 
-receptor than the carboxypeptidase product of Lys-BK,
DLBK (3, 23).
Taken together, these findings suggest that the B
 
1
 
-receptor
plays a role under chronic inflammatory conditions. However,
until now, only hypotheses have been formulated to explain
why and how the B
 
1
 
-receptor is induced (12). Because a better
knowledge of the molecular mechanism involved in the induc-
tion of the B
 
1
 
-receptor will help in understanding its potential
importance in chronic inflammation, we have evaluated the
molecular mechanism of the upregulation of the B
 
1
 
-receptor in
cultured human lung fibroblasts in response to IL-1
 
b 
 
and
DLBK to mimic inflammation and B
 
1
 
-agonist accumulation,
respectively. We report here that upregulation of the B
 
1
 
-recep-
tor by IL-1
 
b 
 
is controlled at the transcriptional level and is
strongly correlated to the activation of transcription factor NF-
 
k
 
B. Further, we report that the novel observation that the B
 
1
 
-
receptor is upregulated by its own agonist involving activation
of protein kinase C (PKC) and NF-
 
k
 
B through pertussis and
cholera toxin-insensitive pathways.
 
Methods
 
Materials
 
FCS and DME were purchased from GIBCO BRL (Gaithersburg,
MD). Penicillin, streptomycin, and glutamine were from Biochrom
(Berlin, Germany). DLBK and [des-Arg
 
10
 
-Leu
 
9
 
]-kallidin were from
Neosystem (Strasbourg, France), and human recombinant IL-1
 
b 
 
was
from Promega Corp. (Madison, WI). Fura-2/AM was purchased from
Molecular Probes (Interchim-Montluçon, France). Pyrrolidinedithio-
carbamate (PDTC), pertussis toxin (PTX), cholera toxin (CHX),
actinomycin D, and PMA were from Sigma Chemical Co. (St. Louis,
MO). PKC inhibitor GF 109203X was obtained from BIOMOL Re-
search Laboratories, Inc. (Plymouth Meeting, PA). IMR 90 cells
(ATCC[R]186-CCL) were purchased from American Type Culture
Collection (ATCC, Rockville, MD) and were used between passage
six and nine. [
 
a
 
-
 
32
 
P]UTP (800 Ci/mmol) was purchased from ICN
Biomedicals, Inc. (Irvine, CA). T7 RNA polymerase was from Euro-
gentec (Seraing, Belgium). p65 (A)-G, p50 (N-19), and c-Rel (N)-G
were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
 
Cell culture and cell treatment
 
IMR 90 cells were grown in DME (4.5 g/liter glucose) supplemented
with 15% FCS, 2 mM glutamine, 1 mM sodium pyruvate, 100 U/ml
penicillin, 100 
 
m
 
g/ml streptomycin. Before mRNA extraction, mem-
brane protein preparation, intracellular calcium concentration ([Ca
 
2
 
1
 
]
 
i
 
)
determination, nuclei isolation, or nuclear extract preparation, IMR
90 cells were washed with PBS and then exposed to the drugs, in the
same culture medium without FCS. Cells were isolated as indicated in
each specific section.
 
Human B
 
1
 
-receptor expression cell line
 
The putative human B
 
1
 
-receptor coding region (
 
2
 
5 to 1,081 bp rela-
tive to the ATG start codon) was subcloned in the expression vector
RcRSV (Invitrogen Corp., San Diego, CA) and transfected into
COS-7 cells using Lipofectamin (GIBCO BRL). 48 h later, selection
for transfectants was initiated by addition of 1 mg/ml G418 (GIBCO
BRL) and resistant colonies were isolated after 2 wk of treatment.
 
Selection, production, and testing of antipeptide antibodies
 
Peptide selection.
 
The transmembrane topology of the primary se-
quence of the B
 
1
 
-receptor (3) was predicted using the TMAP pro-
gram (25), available at the EMBL Web site: http://www.embl-heidel-
berg.de/tmap/tmap_info.html. The hydrophobicity scale was determined
according to Engelman et al. (reference 26; see Fig. 1 
 
A
 
), and com-
pared with that of the B
 
2
 
-receptor. The primary structures of the B
 
1
 
-
and B
 
2
 
-receptor were also compared and three sequences of lesser
homology were selected in putative nontransmembrane regions. The
corresponding peptides, all derived from intracellular loops, were
synthesized and used for immunization.
 
Peptide synthesis.
 
Amino acids were of the L-configuration, and
were purchased from NovaBiochem (Meudon, France) and Neosys-
tem. Peptides derived from the human B
 
1
 
-receptor sequence were
synthesized by solid phase peptide synthesis using the Applied Bio-
systems 431 A peptide synthesizer after a Fmoc chemistry (27). After
deprotection and cleavage, peptides were purified by gel-filtration on
a Sephadex G-25 column (Pharmacia Fine Chemicals, Uppsala, Swe-
den), equilibrated in 5% acetic acid, and their homogeneity checked
by reverse-phase chromatography on a C18 OD300 cartridge
(Brownlee, Touzart and Matignon, Paris, France), using a 40-min lin-
ear (0–80%) acetonitrile gradient in 0.075% trifluoroacetic acid.
Elution was monitored by an Applied Biosystems 1000S diode array
detector (Perkin Elmer, Roissy, France). Peptide molecular weight
was determined by MALDI TOF mass spectroscopy (Brüker, Bre-
men, Germany).
 
Immunizations and antibodies testing.
 
Peptides Y18C and A15C
were coupled to BSA using sulfo m-maleimidobenzoyl 
 
N-
 
hydroxy-
succinimidyl ester as a linker (28). For this purpose, a cysteinyl resi-
due was added at the COOH-terminal end of peptide Y18C to direct
coupling to the carrier protein. K21N was conjugated to succinylated
BSA using 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide as a cou-
pling agent (29). About 1 mg of peptide conjugate was suspended in
Freund’s complete adjuvant and injected subcutaneously to rabbits.
Boosters were administered at least twice at monthly intervals with
0.25 mg of conjugate in incomplete Freund’s adjuvant. Boosters were
repeated until the antibody titer was high enough as judged from in-
direct ELISAs using the immobilized cognate peptide antigen. Typi-
cally, rabbits were bled as soon as antisera were used at 10
 
2
 
4
 
 dilu-
tions for ELISA assays. IgG were purified from rabbit serum by 40%
ammonium sulfate precipitation and extensive dialysis against PBS
at 4
 
8
 
C.
 
ELISAs.
 
Microtiter plates (microtest three flexible assay plates;
Falcon Labware, Cockeysville, MD) were coated with peptides (100 ml
of a 10 mg/ml solution) according to the procedure described in refer-
ence 29. Serial dilutions of crude antisera or purified IgG were then
reacted, followed by a peroxidase-conjugated secondary antibody to
rabbit IgG. Peroxidase activity was measured using 
 
O
 
-phenylenedi-
amine.
 
Western blot analysis
 
After treatment, IMR 90 cells were washed three times with ice-cold
PBS, scraped and lysed in ice-cold lysis buffer (20 mM Tris-HCl, pH
7.4, 50 mM NaCl, 50 mM NaF, 5 mM EDTA, and 20 mM sodium py-
rophosphate). Lysates were centrifuged for 30 min at 25,000 rpm and
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48C, and the pellet was dissolved in ice-cold lysis buffer. The resulting
mixture containing the membrane fraction was sonicated for 10 s. To
concentrate the proteins below 50 kD, the samples were passed
through a microsep microconcentrator with a molecular mass cutoff
of 50 kD (Filtron-France, Colgnieres, France). The protein concen-
tration was determined using Coomassie Brilliant Blue with BSA as
the standard.
Western blot analysis was essentially performed as described pre-
viously (30). Briefly, after addition of Laemmli’s SDS-PAGE sample
buffer (final concentration: 0.16 M Tris-HCl, pH 6.8, 5% SDS [wt/
vol], 25% glycerol [vol/vol], 0.0025% Bromophenol Blue [wt/vol],
13% 2-mercaptoethanol [vol/vol]), the lysates were heated for 5 min
at 1008C. Lysates containing equal amounts of protein (20 mg) were
separated on a 12% (wt/vol) polyacrylamide gel followed by electro-
transfer to ECL nitrocellulose membrane (Amersham Corp., Arling-
ton Heights, IL). The membrane was blocked by incubation for 60
min in 5% nonfat dry milk and 0.1% Tween-20 in PBS (136.8 mM
NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.76 mM KH2PO4) (PBS-T),
washed twice with PBS-T and incubated with B1-receptor antipeptide
antibody (dilution 1/5,000) overnight at 48C. After three washes with
PBS-T, blots were incubated 1 h with a 1/5,000 dilution of a peroxi-
dase-coupled donkey anti–rabbit antibody followed by washing three
times with PBS-T. Revelation of the antibody–protein complex was
done using the ECL-detection reagent (ECL-kit; Amersham Corp.)
followed by exposition to film (Hyperfilm-ECL; Amersham Corp.)
during 1–5 min. Molecular weight markers were from Bio-Rad Labo-
ratories, Richmond, CA (Kaleidoscope prestained standards). In in-
hibition experiments, the antibodies were incubated with the corre-
sponding peptide at a concentration of 10 mg/ml at 48C overnight.
RNA extraction, [32P]riboprobe synthesis, and RNase
protection assay
Total RNA was extracted from confluent IMR 90 cells using the acid
guanidinum thiocyanate-phenol-chloroform extraction method as de-
scribed previously (31). B1-receptor mRNA abundance in IMR 90
cells was determined using RNA–RNA solution hybridization as out-
lined by Sambrook et al. (30). In brief, an [a-32P]-labeled B1-receptor
antisense RNA-probe around 500 bp was prepared by in vitro tran-
scription using the T7-promoter from pBluescript (Stratagene, Inc.,
La Jolla, CA). In this construct the human B1-receptor cDNA was
cloned in the reverse orientation behind the T7-promoter and linear-
ized by BglII (located at 545 bp from the start codon) before in vitro
transcription. The template DNA was digested by RNase-free deoxy-
ribonuclease I (GIBCO BRL). 50 mg of dried cellular RNA was used
in overnight hybridization experiments at 558C in a 30-ml vol of hy-
bridization buffer (80% deionized formamide, 0.4 M NaCl, 0.5 mM
EDTA, 40 mM Pipes, pH 6.7) containing the [32P]-riboprobe. The un-
hybridized portion of the probe was digested with 0.3 ml RNase A
(40 mg/ml) and RNase T1 (700 U/ml). After 2 h at 378C, digestion was
stopped by addition of 5 ml of proteinase K (10 mg/ml) and the sam-
ples were further incubated for 15 min at 378C. Carrier tRNA (10 mg)
and 0.3 ml buffer (38 mM sodium citrate, pH 7.0, 4.2 M guanidine
isothiocyanate, and 20 mM N-lauroylsarcosine) were added to each
tube and protected hybrids were precipitated with isopropyl alcohol.
After washing with 70% ethanol, RNA pellets were dissolved in 10 ml
of sample buffer (97% deionized formamide, 0.1% SDS, 10 mM Tris-
HCl, pH 7.0). [32P]RNA-RNA hybrids were analyzed on a 6% poly-
acrylamide/7 M urea gel. Dried gels were exposed to a Kodak X-Omat
film for 24 h at 2808C. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as the control.
Measurement of the [Ca21]i
The [Ca21]i was determined, as currently done in the laboratory (32),
on adherent cells. After treatment with the IL-1b (200 pM) and
DLBK (0.1 mM) during the indicated time, IMR 90 cells were washed
with Krebs-Ringer buffer (10 mM Hepes, pH 7.4, 145 mM NaCl, 2.5 mM
KH2PO4, 1 mM CaCl2, 1 mM MgSO4, 10 mM glucose, and 0.1% BSA)
and then loaded for 45 min in a 5 mM solution of Fura-2/AM in
Krebs-Ringer buffer at 378C. Before measuring the [Ca21]i in re-
sponse to 0.1 mM DLBK the cells were washed twice with Krebs-
Ringer buffer. Fluorescence measurements were done using a Spex
Fluorilog spectrofluorometer, set for alternative dual wavelength ex-
citation at 340 nm and 380 nm. Light-emitted at 505 nm was collected
by a photomultiplier and passed to a Spex system microcomputer
which averaged the emission collected over a 0.5-s period at each ex-
citation wavelength. Autofluorescence of unloaded cells was found to
be about 18% of the emitted signal and was subtracted from the
Fura-2/AM loaded fluorescence at each excitation wavelength before
calculating the fluorescence ratio R (340/380). As previously de-
scribed, [Ca21]i was calculated from the equation of Grynkiewicz et
al. (33): [Ca21]i 5 Kd 3 (R 2 Rmin/Rmax 2 R) 3 l, where Kd (224 nM)
is the dissociation constant of the complex Fura-2-Ca21 and Rmin,
Rmax, and l are constant parameters depending on the optical system
used. In our experimental conditions they were Rmin, 0.8; Rmax, 16;
and l , 4.
Nuclear run-on experiment
Confluent IMR 90 cells (2 3 106) were treated during 4 h with IL-1b
(200 pM), DLBK (0.1 mM) or with medium only. They were washed
twice with ice-cold PBS, harvested by trypsinization, and resus-
pended in ice-cold 5 ml medium with 15% FCS. Medium was re-
moved by centrifugation (10 min at 400 g) and the cells were resus-
pended in 1 ml of ice-cold lysis buffer (15 mM Hepes, pH 7.5, 0.3 mM
sucrose, 60 mM KCl, 15 mM NaCl, 0.5 mM EGTA, 2 mM EDTA,
14 mM b-mercaptoethanol, 15 mM, 0.15 mM spermine [Sigma Chem-
ical Co.], 0.5 mM spermidine [Sigma Chemical Co.], 1 mM PMSF
[Sigma Chemical Co.], 10 mg/ml leupeptine [Sigma Chemical Co.], 10
mg/ml aprotinine [Sigma Chemical Co.], and 0.04% Nonidet P-40
[Sigma Chemical Co.]) and homogenized by gentle in- and out-pipet-
ting. Cell-lysis and the integrity of the nuclei was examined under a
microscope using Trypan-Blue stain (Sigma Chemical Co.). Nuclei
were collected by centrifugation (5 min at 800 g) and washed twice
with ice-cold lysis buffer. The pelleted nuclei were resuspended in a
190 ml ice-cold solution containing 50 mM Tris-HCl, pH 8.0, 40%
glycerol, 5 mM MgCl2, and 0.1 mM EDTA and rapidly frozen in liq-
uid nitrogen and stored at 2808C until further use. To the 190 ml of
the nuclei suspension were added 50 ml of 53 nuclear run-on buffer
(150 mM Tris-HCl pH 8.0, 750 mM KCl, 25 mM MgCl2, 1 mM
EDTA, 12.5 mM DTT, and 2.5 mM each of ATP, CTP, and UTP)
and 100 mCi of a-[32P]GTP (800 Ci/mmol; ICN Biomedicals, Inc.).
The samples were incubated at 308C for 30 min and the elongated
transcripts were isolated as follows. DNA was degraded by addition
of 5 U of DNase-RNase free (Promega Corp.) for 5 min at 308C. 200
mg yeast tRNA (Boehringer Mannheim Biochemicals, Indianapolis,
IN) was then added as the carrier as well as 300 ml of TES-buffer (10 mM
Tris-HCl, pH 8.0, 10 mM EDTA, and 0.1% SDS). Proteins were elim-
inated by proteinase K (50 mg; Boehringer Mannheim Biochemicals)
digestion for 30 min at 378C followed by an extraction with phenol
(pH 4.3; Sigma Chemical Co.) and precipitation overnight at 2208C
(0.2 M NaCl [final concentration] and 2.5 vol of ethanol). The RNAs
were precipitated by centrifugation (30 min at 12.000 g), resuspended
in 200 ml TES buffer and precipitated twice with 0.2 M ammonium
acetate (final concentration) and 2.5 volumes of ethanol. The final
pellet was resuspended in 500 ml TES-buffer. DNA-samples (1 mg
each) were denatured at 1008C for 5 min in 0.2 M NaOH and placed
on ice. 10 vol of 5 M NaCl were added and the samples were blotted
on a nitrocellulose membrane (Oncor Appligene, Illkirch, France)
pre-wetted with 23 SSC (sodium chloride/sodium citrate) using a
slot-blot device (Hoefer Scientific Instruments, San Francisco, CA).
Every slot was washed three times with 23 SSC followed by fixation
of the DNA by UV-crosslinking (Stratagene, Inc. cross-linker). Pre-
hybridization was performed at 428C overnight in 4 ml of a 20 mM
phosphate buffer, pH 7.4, containing 50% deionized formamide, 1 mM
EDTA, 750 mM NaCl, 0.1% SDS, 53 Denhardt’s reagent, 10% dex-
tran sulfate (Sigma Chemical Co.), 150 mg/ml yeast tRNA, and 100 mg/
ml denaturated salmon sperm DNA (Sigma Chemical Co.). Hybrid-
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ization was initiated by addition of the denatured (2 min at 908C) ra-
diolabeled RNA and continued for 15 h at 428C. The membranes
were then washed with 23 SSC/0.1% SDS, twice at room tempera-
ture (15 min) and twice at 608C (30 min). Autoradiography was per-
formed at 2808C using a Kodak XAR-5 film and intensifying screens.
Nuclear extract preparation and electrophoretic mobility
shift assay
Confluent cultures of IMR 90 cells were harvested by trypsinization,
resuspended in PBS, and washed once with PBS (centrifugation at
3,000 rpm for 5 min). Nuclear extracts were prepared as described
(34) with the following modifications: cells were suspended in a hypo-
tonic buffer (10 mM Hepes, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 300 mM
sucrose, 0.1 mM EGTA, 0.5 mM PMSF, and 0.5 mM DTT) followed
by homogenization by gentle in- and out-pipetting. The homogenates
were centrifuged at 3,000 rpm for 5 min and the pellets containing the
crude nuclei were resuspended in high-salt buffer (20 mM Hepes, pH
7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
0.1 mM EGTA, 0.5 mM PMSF, and 0.5 mM DTT) to extract the nu-
clear proteins. After centrifugation at 14,000 rpm for 15 min, the su-
pernatants were dialyzed for 4 h against a buffer containing 20 mM
Hepes, pH 7.9, 20% glycerol, 100 mM KCl, 0.2 mM EDTA, 0.5 mM
PMSF, and 0.1 mM DTT. Protein concentrations were determined
using Coomassie Brilliant Blue with BSA as the standard.
The electrophoretic mobility shift assay (EMSA) was done with
a consensus double stranded NF-kB oligonucleotide (59-AGTTG-
AGGGGACTTTCCCAGGC-39; Promega Corp.) end-labeled with
[g-32P]ATP (7000 mCi/mmol; ICN Biomedicals, Inc.) using T4-poly-
nucleotide kinase (GIBCO BRL). A typical binding reaction was per-
formed with 10 mg of nuclear protein, 2 mg poly dIdC (Sigma Chemi-
cal Co.), and 0.5 ng of labeled oligonucleotide (specific activity
50,000–200,000 cpm/ng DNA) in binding buffer (10 mM Tris-HCl
[pH 7.5], 5% glycerol, 100 mM NaCl, 1 mM EDTA, and 1 mM DTT).
The binding reaction was carried out at 258C for 45 min. After the re-
action, the samples were electrophorized at 48C for 3.5 h on a 4%
nondenaturating polyacrylamide gel (30:1) in a Tris-Borate-EDTA
buffer system. Dried gels were exposed to a Kodak X-Omat film at
2808C. The specificity of the binding reaction was tested using excess
of unlabeled consensus NF-kB oligonucleotide to compete with the
labeled probe for binding to the nuclear protein. Nonspecific AP-1
oligonucleotide (Promega Corp.) was used as a control. The nuclear
proteins that bound to the NF-kB probe were identified by preincu-
bation of the nuclear extracts for 45 min at 258C with an antibody
(1.5 mg) directed to different protein subunits of NF-kB (p65, p50,
and c-Rel).
The NF-kB-like sequence located about 1,000–1,200 bp upstream
from the transcription initiation sites of the human B1-receptor gene
(NF-kB–HB1, 59-GGCTGGAGAGACCCCCGCCTA-39; NF-kB–
like sequence underlined; reference 35) was used to compete with the
consensus NF-kB sequence. To obtain the double stranded oligonu-
cleotide, single stranded oligonucleotides (sense and antisense) were
synthesized by Eurogentec (Seraing, Belgium). These were dissolved
in buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, and 150 mM NaCl)
to a final concentration of 50 ng/ml, mixed in equal amounts, denatur-
ated (15 min at 708C), and slowly cooled down to room temperature.
These double stranded NF-kB–HB1 oligonucleotides were directly
used in competition assays or end-labeled as described above.
Gene-reporter studies
The human B1-promoter was cloned with and without the NF-kB–
HB1 into pGL3-Basic (Promega Corp.) to verify its ability to drive re-
porter gene-expression in IMR 90 cells upon IL-1b and DLBK stimu-
lation. The human B1-promoter with the NF-kB–HB1 sequence was
PCR-amplified from chromosomal DNA using a sense oligonucle-
otide 59-AACGCTTCTCAGAAACAGTATAG-39 (oligo-1; posi-
tion 49–71; reference 35) with an additional SacI restriction-site
added to the 59-end and an antisense oligonucleotide 59-TGAG-
GACTCGAGAGTGAGAGCTGCTTTTGGAGGAGT-39 (oligo-2;
position 1,299–1,322; reference 35) with an additional HindIII restric-
tion-site added to the 59-end. The human B1-promoter without the
NF-kB–HB1  sequence was PCR-amplified using the same antisense
oligonucleotide above and as sense oligonucleotide was used 59-
TCAGATCTATCCCGGGAGTAATGG-39 (oligo-3; position 175–
198; reference 35) with an additional SacI restriction-site added to the
59-end. The amplification products were cut with SacI and HindIII
and cloned in SacI/HindIII-cut pGL3-Basic. The amplification prod-
ucts were also cloned in the reverse orientation upstream from the re-
porter gene by addition of a SacI restriction-site to the 59-end of
oligo-2 and a HindIII restriction-site to the 59-end of oligo-1 and
oligo-3. To verify the absence of errors introduced during the amplifi-
cation process the inserts were sequenced using an automated se-
quencer (Applied Biosystems, Inc., Foster City, CA). The plasmid
pRL-CMV (Promega Corp.) was used as a control for monitoring the
transfection efficiency by the expression of the Renilla luciferase.
2 mg of each plasmid DNA was used for transient transfection of
IMR 90 cells with Lipofectamin (GIBCO BRL) using the procedures
recommended by the manufacturer. The DNA-containing medium
was removed after 6 h and replaced by normal medium for 48 h. Cells
were stimulated for 2 h by 200 pM IL-1b and 0.1 mM DLBK and har-
vested using Promega’s passive lysis buffer. The remainder of the ex-
periment was performed as described in the technical manual of the
Dual-Luciferase™ Reporter Assay System (Promega Corp.).
Statistical analysis
Results are means6SEM. The differences were tested using the non
parametric Mann-Whitney U test. Differences were considered sig-
nificant at P , 0.05.
Results
Design and testing of human B1-receptor antipeptide antibod-
ies. Three fragments in the cDNA-deduced B1-receptor pri-
Figure 1. Design and testing of B1-receptor antipeptide antibodies. 
(A) Engelman human B1-receptor hydrophobicity scale. The average 
was calculated over seven residues. Selected hydrophilic regions are 
indicated and the sequences of corresponding peptides are shown. 
(B) Specificity of antibodies probed by ELISA. Titer plates were 
coated at 10 mg/ml. The ordinate gives the absorbance at 405 nM and 
the abscissa indicates the antibody dilution.
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mary sequence (3) were selected based on their hydrophilicity,
their positioning in non-transmembrane domains, and their
maximal sequence variability upon comparison with the B2-
receptor. Fragments belonging to intracellular domains an-
swered the best to these criteria and were therefore selected to
raise antisera that could specifically react with the B1-receptor.
Peptides A15C, Y18C, and K21N corresponded to the amino
acid sequences within intracellular loops 3, 4, and to the
COOH-terminal domain of the B1-receptor, respectively (Fig.
1 A). Peptide Y18C was substituted COOH-terminally by a
cysteinyl residue to direct coupling to the carrier protein.
All three conjugates were injected to elicit antipeptide anti-
bodies that could possibly cross react with the B1-receptor.
Antisera with high antibody titers were obtained for each pep-
tide as assessed by ELISA (Fig. 1 B). All antipeptide antibod-
ies also recognized a single band of z 40 kD upon electro-
phoresis of membrane proteins from IMR 90 cells. However,
anti-A15C and anti-Y18C–purified IgGs generated a higher
background staining than anti-K21N upon Western blotting,
so only the latter was used in this study.
Western blot analysis of membrane proteins of IMR 90
cells and COS cells transfected with the human B1-receptor,
using the IgG-purified K21N antibody, showed a band with an
apparent molecular mass of z 40 kD that was absent in mock
transfected COS cells (Fig. 2 A). 40 kD is close to the calcu-
lated molecular mass of the human B1-receptor (38 kD; refer-
ence 3). The specificity of the response of the K21N antibody
was further demonstrated by the ability of the free K21N pep-
tide to inhibit the presence of the 40-kD band (Fig. 2 A, lane
4). These results shows that the 40-kD band identified by the
polyclonal K21N antipeptide antibody is most likely the hu-
man B1-receptor. Furthermore, the 40-kD band was found to
be dependent both on the protein concentration of the extract
(Fig. 2 B, top) and on the IL-1b dose (Fig. 2 B, bottom). Thus,
the K21N antipeptide antibody is a useful analytical tool to
study B1-receptor protein upregulation.
Upregulation of the B1-receptor by IL-1b and B1-agonist
DLBK. Treatment with IL-1b was used as a first approach to
study the mechanism of upregulation of the B1-receptor in
IMR 90 cells. In a preliminary experiment, the time effect (2, 4,
and 6 h) on the induction of the B1-receptor showed that a
maximum expression of the B1-receptor was achieved after 6 h
of treatment with 200 pM IL-1b (data not shown). RNase pro-
tection analysis of B1-receptor mRNA from IMR 90 cells
treated for 6 h with 200 pM IL-1b showed a significant in-
crease in the concentration of B1-receptor mRNA (Fig. 3 A).
The concentration of B1-receptor protein, evaluated by West-
ern blot analysis, was also clearly increased by this treatment
(Fig. 3 B).
Figure 2. Specificity of antipeptide antibodies as analyzed by West-
ern blot. Western blot analysis of the membrane proteins from cells 
expressing the human B1-receptor using the IgG purified from the 
K21N antipeptide antibody (dilution 1/5,000). (A) Membrane pro-
teins (20 mg per lane) from mock transfected COS-7 cells (lane 1), un-
treated IMR 90 cells (lane 2), and COS-7 cells transfected with a plas-
mid expressing the human B1-receptor (lane 3). Lane 4 shows the 
inhibition of the detection of the 40 kD band in COS-7 cells express-
ing the human B1-receptor when the antibody is preincubated (over-
night at 48C) with the K21N peptide at a concentration of 10 mg/ml. 
Molecular mass marker proteins were run simultaneously (lane 5). 
Their molecular masses (kD) are shown on the right-hand side of the 
figure. (B) Western blot analysis of increasing amount of membrane 
proteins (from 5 to 30 mg) from IMR 90 cells treated during 6 h with 
IL-1b (100 pM), (top). Western blot analysis (bottom) of membrane 
proteins (20 mg per lane) from IMR 90 cells—untreated (C) and 
treated 6 h with either 20 pM or 200 pM IL-1b.
Figure 3. Upregulation of the B1-receptor by
IL-1b and DLBK. (A) Detection of the B1-recep-
tor mRNA by RNase protection. (B) Western blot 
analysis of the expression of the human B1-recep-
tor using the IgG purified from K21N (dilution
1:5,000) on membrane proteins (20 mg per lane) 
from IMR 90 cells. C, IMR 90 cells untreated;
IL-1b, IMR 90 cells treated 6 h with 200 pM
IL-1b; DLBK, treatment for 6 h with 0.1 mM 
DLBK; DLBK 1 anti B1, DLBK treatment (6 h, 
0.1 mM) in presence of the specific B1-antagonist 
[des-Arg10-Leu9]-kallidin (1 mM). (C and D) 
DLBK induces B1-receptor mRNA and protein 
expression in a dose-dependent manner. Cells 
were treated for 6 h with medium only (C) or in-
creasing concentrations of DLBK (1–1000 nM). 
The autoradiographs shown are representative of 
four independent experiments.
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Interestingly, similar results were found by treatment of
IMR 90 cells with the B1-agonist DLBK. DLBK increased
both B1-receptor mRNA and protein in a dose-dependent
manner from 1 nM to 1 mM (Fig. 3, C and D). The observed
upregulation of the B1-receptor by DLBK was completely pre-
vented by the use of the high affinity B1-antagonist [des-Arg10-
Leu9]-kallidin, indicating that the upregulation of the B1-
receptor by its own agonist acts via the present population of
cell surface B1-receptors (Fig. 3, A and B). Treatment of the
cells with the antagonist alone did not induce any effect on B1-
receptor gene expression (not shown).
Effect of the induction of the B1-receptor on the [Ca21]i mo-
bilization induced by DLBK. Functional B1-receptors were
synthesized during the upregulation by IL-1b and DLBK since
a significant increase in the mobilization of [Ca21]i induced by
DLBK (0.1 mM) compared with the control was observed (Fig.
4). DLBK induced the classical biphasic increase in [Ca21]i
mobilization (32). However, only the first, transient phase was
increased, whereas the sustained phase was not affected by the
treatment with IL-1b or DLBK (Table I). Moreover, treat-
ment of IMR 90 cells either with IL-1b or DLBK was without
effect on the B2-receptor stimulation since the [Ca21]i increase
induced by BK (0.1 mM) was unchanged (Table I). The in-
crease in the mobilization of [Ca21]i by DLBK was selectively
inhibited by the B1-antagonist [des-Arg10-Leu9]-kallidin (not
shown).
Transcriptional activation of B1-receptor expression. To
determine whether the B1-receptor upregulation was due to
the activation of transcription or an increase in stabilization of
B1-receptor mRNA, IMR 90 cells were stimulated with me-
dium only, IL-1b (200 pM), or DLBK (0.1 mM) for 4 h before
addition of transcriptional inhibitor actinomycin D (6 mg/ml).
B1-receptor mRNA expression was examined by RNase-pro-
tection at t 5 0, 30, 60, 120, and 240 min after addition of acti-
nomycin D (Fig. 5 A). Both IL-1b and DLBK did not signifi-
cantly alter the stability of B1-receptor mRNA, their half-lives
were comparable to the control (half-lives: 121615, 115613,
and 109616 min for medium only, IL-1b, and DLBK, respec-
tively). To further confirm the effect of IL-1b and DLBK on
B1-receptor mRNA induction, nuclear run-on experiments
were performed. IMR 90 cells were treated for 4 h with me-
dium only, IL-1b (200 pM), or DLBK (0.1 mM) followed by
isolation of the nuclei. Fig. 5 B shows the results of a typical
run-on assay in which IL-1b and DLBK clearly stimulated
transcriptional activation of the B1-receptor. Taken together,
these results show that both IL-1b and DLBK induce tran-
scriptional activation of the B1-receptor.
IL-1b and DLBK induce transcription factor NF-kB. For
more insight into the transcription mechanism of B1-receptor
upregulation, we decided to study the activation of transcrip-
tion factor NF-kB. Transcription factor NF-kB (36, 37) was
chosen as the transcription factor to be studied for the follow-
ing two reasons: (a) IL-1b often induces transcription factor
NF-kB (36, 37, 38); and (b) computer analysis of the promoter
region of the human B1-receptor revealed the presence of a
NF-kB–like sequence (35).
The EMSA was used to study the involvement of transcrip-
tion factor NF-kB in B1-receptor upregulation (Fig. 6). Nu-
clear extracts harvested from untreated (control) IMR 90 cells
demonstrated little binding of a double stranded oligonucle-
otide containing the consensus NF-kB recognition sequence
Figure 4. Upregulation by IL-1b and 
agonist DLBK results in functional B1-
receptors. Increase in intracellular
calcium [Ca21]i induced in adherent 
IMR 90 cells by 0.1 mM DLBK on un-
treated cells (C); cells treated for 6 h 
with 200 pM IL-1b (IL-1b); cells 
treated 6 h with 0.1 mM DLBK 
(DLBK). Arrows indicate the stimula-
tion with DLBK. B1-receptor stimula-
tion was performed in a calcium con-
taining medium (1 mM). The profiles 
are representative for four independent 
experiments (see Table I).
Table I. Effect of 0.1 mM DLBK and 0.1 mM BK on the 
Transient Phase (Peak) and Sustained Phase (Plateau) of 
Increase in [Ca21]i from IMR 90 Cells Treated either with 200 
pM IL-1b or with 0.1 mM DLBK. B1 and B2-receptor 
Stimulation was Performed in a Calcium Containing Medium
(1 mM)
Stimulation Phase
Cell treatment
Control IL-1b DLBK
DLBK (0.1 mM) Transient 270620 nM 395625 nM* 390615 nM*
Sustained 210615 nM 205620 nM 212610 nM
BK (0.1 mM) Transient 430620 nM 415615 nM 420612 nM
Sustained 150610 nM 135610 nM 152615 nM
The results are the mean6SEM of four independent experiments. *P ,
0.05 compared to the respective control value.
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(36), with low interassay variations (Fig. 6, control). However,
after treatment for 1 h 45 min with IL-1b (200 pM), NF-kB–
DNA binding activities were identified (Fig. 6 A, bracket). The
specificity of the observed DNA–protein interaction was con-
firmed by the ability of excess unlabeled NF-kB oligonucle-
otide (specific competitor) to inhibit binding, whereas the ad-
dition of nonspecific oligonucleotide (a tandem repeat of the
AP-1 consensus motif) did not block the binding (Fig. 6 A).
Further characterization of the nuclear proteins binding to the
NF-kB motif was obtained by preincubation of the nuclear ex-
tracts with antibodies against the p65, p50, and c-Rel protein
subunits of NF-kB. This resulted in retardation (supershift) of
the NF-kB–DNA binding activity in case of p65. Antibodies
against the p50 and cRel subunits of NF-kB were also able to
reduce the NF-kB–DNA binding activity. This suggests that in
IMR 90 cells, IL-1b induced nuclear binding proteins contain-
ing p65, p50, and c-Rel forms of NF-kB (Fig. 6 B). Stimulation
of cells with 40 pM IL-1b for 1 h 45 min gave similar results
(not shown).
Treatment of IMR 90 cells with the B1-agonist DLBK (0.1
mM) for 1 h 45 min resulted in a significant increase in the den-
sity of a NF-kB–DNA binding activity, indicating the accumu-
lation of NF-kB protein in the nucleus (Fig. 6 C, bracket).
Competition experiments with unlabeled specific and nonspe-
cific oligonucleotides confirmed the specificity of the binding
reaction (Fig. 6 C). Preincubation of the nuclear extracts with
antibodies against the p65, p50, and c-Rel NF-kB subunits re-
sulted in inhibition of the NF-kB–DNA binding activity with
all antibodies (Fig. 6 D). Inhibition of the NF-kB–DNA bind-
ing activity was not observed when the extracts were preincu-
bated with an unrelated nonspecific antipeptide antibody di-
rected against the human B1-receptor K21N (1.5 mg, not
shown). The disappearance of the NF-kB–DNA binding activ-
Figure 5. (A) Effect of IL-1b and DLBK on B1-receptor mRNA sta-
bility. IMR 90 cells were stimulated for 4 h with medium only, IL-1b 
(200 pM) and DLBK (0.1 mM). Cells were harvested for RNA-
extraction at various time intervals after addition of actinomycin D
(6 mg/ml). Total RNA (50 mg) was analyzed with the RNase protec-
tion assay using 32P-labeled B1-receptor and GAPDH probes. The 
densitometric values of each band were evaluated using the Personal 
Densitometer SI (Molecular Dynamics, Sunnyvale, CA). B1-receptor 
signals were corrected for differences in total RNA quantities using 
GAPDH. The corrected density of each time point was then divided 
by that of the B1-receptor mRNA density at the time of actinomycin 
D addition (initial). Results are mean6SEM from three separate ex-
periments. (B) IL-1b and DLBK activate B1-receptor gene transcrip-
tion. Cells were stimulated with medium only, IL-1b (200 pM) and 
DLBK (0.1 mM) for 4 h followed by nuclei isolation. Transcripts were 
elongated in the presence of a-[32P]GTP before RNA isolation. Ra-
diolabeled nuclear RNA was hybridized with DNA samples of 
pBR322 plasmid, human B1-receptor and GAPDH housekeeping 
gene immobilized on nitrocellulose membranes. The autoradiograph 
of one representative experiment is shown.
Figure 6. Induction of transcription factor NF-kB by IL-1b and 
DLBK evaluated by EMSA of nuclear extracts. The EMSA was per-
formed with 32P-labeled consensus NF-kB oligonucleotide and with 
IMR 90 nuclear extracts as described in Methods. Cells were treated 
for 1 h 45 min with 200 pM IL-1b (A and B) or 0.1 mM DLBK (C and 
D); control, untreated cells; specific competitor, unlabeled consensus 
NF-kB oligonucleotide added (the fold molar excess to labeled
NF-kB oligonucleotide is indicated); nonspecific competitor, unla-
beled AP-1 consensus motif added (the fold molar excess to labeled 
NF-kB is indicated); p65, p50, and c-Rel, preincubation of the nuclear 
proteins with antibody directed against the p65, p50, and c-Rel sub-
units of NF-kB, respectively (1.5 mg); ns, nonspecific. A bracket indi-
cates the NF-kB–DNA binding activity.
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ity upon incubation with antibodies directed against the differ-
ent NF-kB subunits was specific since an antibody concentra-
tion dependent decrease in NF-kB–DNA binding activity was
observed (Fig 7 A, shown for p65; p50 and c-Rel not shown)
which did not significantly affect the non-specific binding (Fig.
7 A, ns). These results suggested that the NF-kB complexes ac-
tivated by DLBK contain the p65, p50, and cRel subunits of
NF-kB (Fig. 7 A).
The recent publication of a NF-kB–like sequence in the
promoter region of the human B1-receptor gene (NF-kB–HB1;
reference 35) allowed us to perform competition experiments
between the commercially available consensus NF-kB and the
NF-kB–HB1 sequence located in the promoter region of the
B1-receptor (Fig. 7 B). Interestingly, binding of the consensus
NF-kB oligonucleotide to the NF-kB complex induced by
DLBK was clearly displaced by 200-fold molar excess of the
NF-kB–HB1 oligonucleotide. We only reduced the binding of
the consensus NF-kB oligonucleotide to the IL-1b–induced
NF-kB complexes with a 200-fold molar excess of NF-kB–HB1
oligonucleotide (Fig. 7 B, bracket). A complete displacement
was obtained by using a 500-fold molar excess of NF-kB–HB1
oligonucleotide (not shown). To prove direct binding of the
NF-kB–like sequence to NF-kB proteins, the NF-kB–HB1 oli-
gonucleotide was labeled and used in EMSA analysis (Fig. 7 C).
As for the consensus NF-kB oligonucleotide, NF-kB–DNA
binding activity was observed using the NF-kB–like sequence
in IL-1b and DLBK treated IMR 90 cells. DLBK-induced NF-
kB–DNA binding activity was prevented by pretreatment with
the high affinity B1-antagonist [des-Arg10-Leu9]-kallidin. Com-
petition experiments with unlabeled specific and nonspecific
oligonucleotides confirmed the specificity of the binding reac-
tion. Preincubation of the nuclear extracts with antibodies
against the p65, p50, and c-Rel NF-kB subunits resulted in
inhibition of the NF-kB–DNA binding activity with all anti-
bodies.
IL-1b and DLBK induce reporter gene-expression directed
by the human B1-promoter. The above results suggest a corre-
lation between NF-kB activation and B1-receptor upregula-
tion. This relationship was further studied by the ability of
IL-1b and DLBK to drive reporter gene-expression under
control of the human B1-receptor promoter. The human B1-
receptor promoter with and without the NF-kB–like sequence
was cloned upstream from the luciferase gene of pGL3-Basic.
These constructs were used to transiently transfect IMR 90
Figure 7. NF-kB–DNA binding activities in extracts of cells
treated for 1 h 45 min with IL-1b (200 pM) and DLBK (0.1 M). (A) 
Competition between labeled NF-kB oligonucleotide and p65 anti-
body in DLBK treated cells (different concentrations of p65 antibody 
used are indicated). (B) Competition of 32P-labeled consensus NF-kB 
oligonucleotide and unlabeled NF-kB–like sequence, located in the 
promoter region of the human B1-receptor gene (NF-kB–HB1), be-
tween NF-kB complexes induced by DLBK and IL-1b treatment. 
Unlabeled NF-kB–HB1 oligonucleotide was added in z 200-fold mo-
lar excess to the consensus NF-kB oligonucleotide. (C) Analysis of 
NF-kB–DNA binding activities using radiolabeled NF-kB–like se-
quence (NF-kB–HB1). anta B1, DLBK treatment (1 h 45 min, 0.1 mM) 
in presence of the specific B1-antagonist [des-Arg10-Leu9]-kallidin 
(1 mM); specific competitor, unlabeled NF-kB–HB1 oligonucleotide 
added (100-fold excess); nonspecific competitor, unlabeled AP-1 con-
sensus motif added (100-fold excess); p65, p50, and c-Rel, preincuba-
tion of the nuclear proteins with antibody directed against the p65, 
p50, and c-Rel subunits of NF-kB, respectively (1.5 mg); ns, nonspe-
cific. A bracket indicates the NF-kB–DNA binding activity.
Figure 8. Gene-reporter assays with the human B1-receptor pro-
moter. IMR 90 cells were transiently transfected using pGL3-Basic 
with the following B1-receptor promoter elements cloned upstream 
from the luciferase gene: the human B1-receptor promoter with and 
without the NF-kB–like sequence in the normal orientation (pro-
moter 1/2 NF-kB) and in the reverse orientation (promoter 1/2 
NF-kB [rev. orien.]). Then cells were simulated during 2 h with me-
dium only, IL-1b (200 pM) and DLBK (0.1 mM) followed by analysis 
of luciferase activities in crude cell extracts. Differences in transfec-
tion efficiencies were corrected by assaying the Renilla luciferase ac-
tivities of plasmid pRL-CMV which was cotransfected with the con-
structs. The results are shown as the percentage of the maximum 
luciferase activity observed with the IL-1b–induced promoter 1 NF-kB 
construct. Each value is the mean6SEM (n 5 3).
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cells and measure reporter gene-expression after stimulation
(Fig. 8). Whereas the control plasmid (pGL3-Basic) showed
only low level luciferase expression and showed no response to
IL-1b (200 pM) or DLBK (0.1 mM) treatment (2 h), the con-
struct with the B1-receptor promoter induced significant lu-
ciferase expression upon stimulation with both IL-1b and
DLBK. However, the IL-1b- and DLBK-induced luciferase
expression of the construct in which we deleted the NF-kB like
sequence from the B1-receptor promoter was significantly
lower, but still about fivefold higher than the value obtained
with pGL3-Basic alone. Cloning of the B1-receptor promoter
in the reverse orientation did not significantly drive luciferase
expression. These results suggest that IL-1b and DLBK-induced
NF-kB activation participates in B1-receptor expression via the
NF-kB–like sequence located in the promoter region. Further
support for this relationship was obtained by the use of the an-
tioxidant PDTC, which is a known inhibitor of transcription
factor NF-kB activation (39). A PDTC dose-dependent inhibi-
tion on DLBK-induced B1-receptor upregulation was ob-
served when cells were pretreated 30 min before DLBK stimu-
lation (Fig. 9). PDTC at a concentration of 500 mM decreased
strongly B1-receptor upregulation induced by IL-1b and
DLBK at the levels of mRNA and protein expression (Fig. 10,
A and B). Pretreatment with PDTC resulted in a decreased
activation of transcription factor NF-kB by both DLBK and
IL-1b (Fig. 10 C). These results suggest that transcription fac-
tor NF-kB participates in B1-receptor upregulation induced by
DLBK and IL-1b.
Effect of bacterial toxins and involvement of PKC on
DLBK-induced B1-receptor expression and NF-kB activa-
tion. Cloning studies showed that B1-receptors are 7-trans-
membrane G protein–coupled receptors (3). To determine
which type of Ga protein is involved in DLBK-induced B1-
receptor upregulation, we treated IMR 90 cells with either
PTX (100 nM) or CHX (1 mM) for 4 h before stimulation
with DLBK (0.1 mM) for 4 h. RNase protection analysis of B1-
receptor mRNA did not show any differences in bacterial
toxin-treated cells compared with nontreated control cells
(Fig. 11 A). This was also observed on DLBK-induced NF-kB
activation (Fig. 11 B). 12-h pretreatment with CHX and PTX
was also without effect (not shown). However, pretreatment
with PKC inhibitor GF 109203X (30 min, 1 mM) inhibited
DLBK-induced B1-receptor mRNA expression (Fig. 11 C).
Direct stimulation of PKC by phorbol ester PMA (100 nM,
4 h) resulted in upregulation of B1-receptor message that was
also clearly inhibited by GF 109203X, indicating the specificity
of the inhibitor. PKC inhibitor GF 109203X also significantly
inhibited DLBK-induced NF-kB activation (Fig. 11 D).
Discussion
An increasing number of observations show an upregulation
of the bradykinin B1-receptor under chronic inflammatory
conditions that suggests a role for this receptor in these situa-
tions. However, it is still unclear why and how this receptor is
induced (12). For this reason, we have studied the molecular
mechanism of B1-receptor upregulation under in vitro inflam-
matory conditions (IL-1b stimulation) and during prolonged
Figure 9. Inhibition of DLBK-induced B1-receptor mRNA upregula-
tion by antioxidant PDTC. IMR 90 cells were preincubated (30 min) 
with PDTC at three different concentrations before DLBK (0.1 mM) 
stimulation for 6 h. Control, untreated cells; DLBK, cells stimulated 
with DLBK; PDTC, cells pretreated with different concentrations 
(indicated) of PDTC before stimulation with DLBK. The autoradio-
graph of one representative experiment is shown.
Figure 10. The effect of PDTC on B1-receptor upregulation. IMR 90 
cells were stimulated with IL-1b (200 pM) and DLBK (0.1 mM) for 
6 h for Western blot (20 mg per lane) and RNase protection analysis, 
and 1 h 45 min for EMSA analysis. PDTC (500 mM) was added 30 
min before drug treatment. (A) RNase protection analysis of B1-
receptor mRNA expression in the presence or absence of PDTC. (B) 
Western blot analysis of B1-receptor protein expression in the pres-
ence or absence of PDTC. PDTC, treatment with (1) or without (2) 
PDTC. (C) EMSA-analysis of NF-kB activation in the presence or 
absence of PDTC. Control, untreated cells; IL-1b, cells treated with 
IL-1b; DLBK, cells treated with DLBK; IL-1b 1 PDTC, treatment 
with IL-1b and PDTC; DLBK 1 PDTC, treatment with DLBK and 
PDTC.
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agonist stimulation in cultured human lung fibroblasts (IMR
90 cells). The results presented here show that B1-receptor up-
regulation by IL-1b is regulated at the transcriptional level
involving activation of transcription factor NF-kB and provide
the first evidence that the B1-receptor is up-regulated by its own
agonist. Both IL-1b and the B1-agonist activate transcription
factor NF-kB, a transcription factor now recognized as playing
a key role in immune and inflammatory responses (22, 40).
The observation of local production of IL-1b during in-
flammation accompanied by B1-receptor up-regulation in sev-
eral tissues has resulted in the hypothesis that this cytokine is
directly involved in B1-receptor upregulation (12). Further-
more, binding studies have shown a sevenfold increase in B1-
receptor binding sites after treatment of IMR 90 cells with IL-1b
(3). For these reasons we have chosen IL-1b as an in vitro
stimulus to study B1-receptor up-regulation in cultured human
lung fibroblasts. B1-receptor protein expression was examined
with immunoblotting using antipeptide antibodies. This rela-
tively new strategy to obtain antibodies when no purified pro-
tein is available uses small synthetic peptides derived from
cDNA sequences. All our tests showed that the antipeptide
antibodies were B1-receptor specific and thus were a good ana-
lytical tool to study the human B1-receptor expression. Re-
cently, antipeptide antibodies directed against the human B2-
receptor have been successfully used to study the involvement
of extracellular loops in B2-receptor ligand binding (41, 42).
Our data confirm, at the mRNA and protein levels, that IL-
1b upregulates B1-receptor expression. Furthermore, the func-
tional response to the B1-agonist DLBK as reflected by in-
creased calcium mobilization, was enhanced following IL-1b
treatment. To our knowledge, this is the first clear demonstra-
tion of B1-receptor upregulation by IL-1b studied at different
levels. This observed upregulation is the consequence of tran-
scription activation as shown by the results of both B1-receptor
mRNA half-life and nuclear run-on experiments. Electro-
phoretic mobility shift assays were used with nuclear extracts
from stimulated IMR 90 cells to examine the transcription mech-
anism for IL-1b–induced B1-receptor expression. A DNA-
binding activity specific for transcription factor NF-kB was ob-
served after IL-1b treatment, which was strongly correlated to
B1-receptor upregulation since both receptor expression and
NF-kB were inhibited by antioxidant PDTC, a known NF-kB
inhibitor. This IL-1b–induced DNA-binding activity could also
bind to the NF-kB–like sequence located in the promoter re-
gion of the B1-receptor. Furthermore, gene-reporter experi-
ments showed that this NF-kB–like sequence could contribute
to IL-1b–induced B1-receptor mRNA expression.
We report here the novel observation that the bradykinin
B1-receptor is upregulated by its own agonist DLBK. Usually,
the activation of receptors by their agonists induces downregu-
lation of the receptor. However, a few reports have shown the
upregulation of G protein–coupled receptors, including the
b3-adrenergic (43), the dopamine D2 (44), and the angiotensin
II (45) receptors. Multiple mechanisms seem to be involved,
like an increased efficiency of translation, modulation of
cAMP production, stabilization of mRNA or stabilization of
the receptor by ligands, depending upon the cells or receptor
which is studied. The upregulation of the human B1-receptor
was identified by an increase in both B1-receptor mRNA and
protein, as well as the B1-agonist–induced increase in free
cytosolic calcium. Since this effect was fully prevented by the
B1-antagonist [des-Arg10-Leu9]-kallidin, the B1-receptor up-
regulation resulted from the stimulation of the preexistent
population of cell-surface B1-receptors. Furthermore, as ob-
served for IL-1b, B1-receptor upregulation by DLBK is the
consequence of transcription activation. In IMR 90 cells, the
B1-receptor was coupled to PTX and CHX insensitive G pro-
teins. However, our results suggest that the transduction path-
way activated by the B1-agonist involves PKC activation.
These observations indicate that the B1-receptor might be cou-
pled to the Gaq/11 subfamily which is insensitive to PTX but
couples to the known b-isoforms of phospholipase C (46–49).
Indeed, recombinant stable expression of the B1-receptor in
Chinese hamster ovary cells has recently demonstrated that
the human B1-receptor can be coupled to the Gaq/11 subfam-
ily (23).
As observed in IL-1b treatment, activation of transcription
factor NF-kB was observed in nuclear extracts of DLBK-
Figure 11. Absence of effects of pretreatment 
with PTX (100 nM) and CHX (1 mM) for 4 h 
on DLBK-induced (0.1 mM, 4 h) B1-receptor 
mRNA expression (A) and NF-kB activation 
(B). Inhibition of B1-receptor mRNA expres-
sion (C) and NF-kB activation (D) by 30-min 
pretreatment with 1 mM GF 109203X (1GF) 
before stimulation with DLBK (0.1 mM) or 
PMA (100 nM) for 4 h. Control, medium only. 
The autoradiographs of one representative ex-
periment are shown.
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treated cells which was well correlated with B1-receptor upreg-
ulation. Moreover, EMSAs with the NF-kB–like sequence, the
effect of PDTC, and B1-receptor promoter gene-reporter stud-
ies with DLBK showed a clear correlation between activation
of transcription factor NF-kB, the NF-kB–like sequence, and
B1-receptor transcription activation. Transcription factor NF-kB
is activated by phosphorylation and subsequent degradation of
IkB which is an inhibitory protein that retains NF-kB in its in-
active form in the cytosol. Upon dissociation of IkB, NF-kB
translocates to the nucleus (36, 37, 40). The signaling pathways
of NF-kB activation by IL-1b have been studied in some detail
now (38), but very little is known about the transduction path-
ways of G protein–coupled receptor-simulated NF-kB activa-
tion. Our results indicate the involvement of PKC in NF-kB
activation by DLBK, a kinase that is able to activate NF-kB
(50). The precise mechanism of DLBK-induced NF-kB activa-
tion remains to be investigated, however. The B1-receptor is not
the only protein upregulated by NF-kB, many inflammatory
genes are activated by NF-kB. The NF-kB activating proin-
flammatory cytokines IL-1b and TNFa are upregulated by
NF-kB itself which may lead to amplification and perpetuation
(through feedforward loops) of the inflammatory process (22).
From a pathophysiological point of view, the observation
that the B1-receptor is upregulated by its own agonist, should
be kept in mind to better understand the role of the B1-recep-
tor in the pathological situations where the B1-receptor is
likely to be induced, such as chronic inflammation (12), hyper-
algesia (24), and septic shock (51). Other pathologies may also
be concerned by this B1-upregulation mechanism because it
has been reported that, in cultured cells, the B1-agonist stimu-
lates cell proliferation (32, 52) but also collagen production
(52). Such effects have to be related to pathologies where fi-
brotic processes are observed. Furthermore, the accumulation
of the B1-agonist can occur in situations where the activity of
the ACE is either decreased, or inhibited by the use of ACE
inhibitors. Indeed, treatment with ACE inhibitors favors the
conversion of B2-agonists into B1-agonists by arginine carboxy-
peptidase M and N (12). In this respect a decrease in ACE
activity has been reported in animal models of fibrogenic lung
injury (53, 54). Our results also agree with Nwartor and Whal-
ley’s study (55) which reported that treating rabbits with ACE
inhibitors made these animals in vivo responsive to the B1-
agonist [des-Arg9]-BK. Consistent with our results, it is
likely that potentiation of [des-Arg9]-BK formation upregu-
lates the B1-receptor and thereby explains the increased re-
sponse to the B1-agonist after ACE inhibitor treatment in their
studies.
In summary, we present here the first analysis of the regu-
lation of the expression of the human kinin B1-receptor. The
evidence of a homologous upregulation appears as an impor-
tant new feature of this receptor. This observation introduces a
new difference between the mechanisms of expression regula-
tion of B1- and B2-receptors since the B2-receptor is downregu-
lated by prolonged exposure to its agonist (56), which is most
likely linked to receptor internalization (23). Under inflamma-
tory conditions B1-receptors may take the relay of B2-receptor
function (12) and recently it was shown that BK, the high affin-
ity B2-receptor agonist, activates both NF-kB and IL-1b pro-
duction (21). Prolonged B2-receptor stimulation under inflam-
matory conditions in vivo thus could lead to the induction of
the B1-receptor, an effect that is likely to be amplified by the
B1-agonist DLBK. Under these pathological conditions the
use of mixed B1- and B2-antagonists (57) will be appropriate to
counteract all kinin related effects.
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